Figure 1. Participant Flow in a Study of Single-Dose Psilocybin Treatment for Major Depressive Disorder.

^aIncludes all potential participants from the point of telephone screening.

^bOne participant randomized to receive psilocybin received niacin and was included in the niacin group for the safety population.

^cReasons for exclusion included missing day 8 or day 43 central rater Montgomery-Asberg Depression Rating Scale assessments or major protocol deviations.

See eFigure 1 in Supplement 3 for additional details.